864754-16-5

Basic information

• Product Name: 1-(ETHOXYCARBONYLMETHYL)-1H-PYRAZOLE-4-BORONIC ACID, PINACOL ESTER
• Synonyms: 1-(ETHOXYCARBONYLMETHYL)-1H-PYRAZOLE-4-BORONIC ACID, PINACOL ESTER;[4-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-PYRAZOL-1-YL]-ACETIC ACID ETHYL ESTER;Ethyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-acetate;ethyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetate;ethyl 2-[4-(tetraMethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]acetate;1-(Ethoxycarbonylmethyl)pyrazole-4-boronic Acid Pinacol Ester;1-(Ethoxycarbonylmethyl)-1H-pyrazole-4-boronic acid pinacol ester 97%;1H-Pyrazole-1-acetic acid,4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-,ethyl ester
• CAS NO: 864754-16-5
• Molecular Formula: C₁₃H₂₁BN₂O₄
• Molecular Weight: 280.13
• Product Categories: Boronate Esters;Boronic Acids and Derivatives;Chemical Synthesis;Heteroaryl Boronate Esters;Organometallic Reagents
• Mol File: 864754-16-5.mol

Chemical Properties

• Boiling Point: 390.8°C at 760 mmHg
• Flash Point: 110 °C
• Appearance: /
• Density: 1.12g/cm³
• Vapor Pressure: 2.57E-06mmHg at 25°C
• Refractive Index: n20/D 1.4814
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 1.49±0.10(Predicted)
• CAS DataBase Reference: 1-(ETHOXYCARBONYLMETHYL)-1H-PYRAZOLE-4-BORONIC ACID, PINACOL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(ETHOXYCARBONYLMETHYL)-1H-PYRAZOLE-4-BORONIC ACID, PINACOL ESTER(864754-16-5)
• EPA Substance Registry System: 1-(ETHOXYCARBONYLMETHYL)-1H-PYRAZOLE-4-BORONIC ACID, PINACOL ESTER(864754-16-5)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 864754-16-5(Hazardous Substances Data)

Usage

Chemical Properties

liquid

Uses

1-(Ethoxycarbonylmethyl)-1H-pyrazole-4-boronic acid pinacol ester

InChI:InChI=1/C13H21BN2O4/c1-6-18-11(17)9-16-8-10(7-15-16)14-19-12(2,3)13(4,5)20-14/h7-8H,6,9H2,1-5H3

Upstream product

• 82231-58-1 2-(4-bromopyrazol-1-yl)acetic acid ethyl ester 
• 73183-34-3 bis(pinacol)diborane 
• 269410-08-4 pyrazole-4-boronic acid pinacol ester 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 1040377-13-6 C₂₁H₂₀Cl₂FN₃O₃ 
• 1350377-59-1 ethyl 2-(4-(5-fluoro-4-(2-(1-hydroxycyclobutyl)thiazol-5-yl)-1-tosyl-1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-pyrazol-1-yl)acetate 
• 1407831-88-2 (R)-2-(4-(6-(4-cyanophenyl)1,4-dimethyl-5,6-dihydro-4H-benzo[b][1,2,4]triazolo[4,3-d][1,4]diazepin-8-yl)-1H-pyrazol-1-yl)acetamide 
• 1407834-80-3 (R)-2-(4-(6-(4-cyanophenyl)1,4-dimethyl-5,6-dihydro-4H-benzo[b][1,2,4]triazolo[4,3-d][1,4]diazepin-8-yl)-1H-pyrazol-1-yl)acetic acid 
• 1607005-77-5 (4-{4-[4-(tert-butoxycarbonylaminomethyl)-3-fluorophenyl]-7H-pyrrolo[2,3-d]pyrimidin-6-yl}pyrazol-1-yl)acetic acid ethyl ester 

Relevant articles and documents

AMINOPYRIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF

The present invention discloses an aminopyridine compounds, a preparation method and use thereof, particularly the aminopyridine compounds of formula (I), pharmaceutical compositions containing the same, the method for preparing the same and the use thereof in the prophylaxis or treatment of an adenosine A2a receptor related disease.

DISUBSTITUTED PYRAZOLE COMPOUNDS

The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and no

Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors

A series of 2-amino-N-benzylpyridine-3-carboxnamides, 2-amino-N- benzylpyridine-3-sulfonamides and 2-amino-3-benzylthiopyridines against c-Met were designed by means of bioisosteric replacement and docking analysis. Optimization of the 2-amino-3-benzylthiopyridine scaffold led to the identification of compound (R)-10b displaying c-Met inhibition with an IC 50 up to 7.7 nM. In the cytotoxic evaluation, compound (R)-10b effectively inhibited the proliferation of c-Met addictive human cancer cell lines (IC50 from 0.19 to 0.71 μM) and c-Met activation-mediated cell metastasis. At a dose of 100 mg/Kg, (R)-10b evidently inhibited tumor growth (45%) in NIH-3T3/TPR-Met xenograft model. Of note, (R)-10b could overcome c-Met-activation mediated gefitinib-resistance, which indicated its potential use for drug combination. Taken together, 2-amino-3-benzylthiopyridine scaffold was first disclosed and exhibited promising pharmacological profiles against c-Met, which left room for further exploration.

KINASE INHIBITOR COMPOUNDS

Pyridine and pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.